Form 4: Sutro Biopharma Executive Hans-Peter Gerber Reports Stock Transactions
SEC Form 4 Filing
Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On September 18, 2024, Hans-Peter Gerber, the Chief Scientific Officer of Sutro Biopharma, had 37,500 shares of common stock vest from restricted stock units (RSUs).
- Simultaneously, 13,380 shares were withheld by the issuer to cover income tax obligations at a price of $3.95 per share.
- Following these transactions, Gerber directly owns 24,120 shares of common stock.
- Gerber also holds 112,500 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by an executive, with no inherent positive or negative implications for the company's overall prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions have a minor impact on the overall shareholding structure of the company.
Key Dates
| Date | Description |
|---|---|
| 09/18/2024 | Date of the stock transactions: vesting of RSUs and tax withholding. |
| 09/18/2024 | RSU award vests annually as to 1/4th of the total award beginning on this date. |
| 09/18/2027 | Expiration date of the Restricted Stock Units. |
| 09/20/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.